Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.11, moving +1.63% from the previous trading session. The stock's performance was ahead of the S&P 500's daily gain of 0.11%.

Don't call Recursion Pharmaceuticals (NASDAQ: RXRX) a biotech company. Its management prefers the term "TechBio." While many have been skeptical about TechBio in the past, the reception is changing ...

NEW YORK and SALT LAKE CITY, March 31, 2026 (GLOBE NEWSWIRE) -- Citeline, a leader in clinical solutions for the life sciences industry, today announced an expanded strategic partnership with ...

The concept of a meme stock was born about five years ago. It refers to a publicly traded company that gains substantial market value practically overnight (sometimes literally) due to significant ...

We believe that Recursion RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is likely to beat expectations when it reports second-quarter 2024 results. The ...

The novelist Blake Crouch was searching for an idea for his next book, and he'd hit a wall. BLAKE CROUCH: And then I came across this article about two MIT scientists who were implanting false ...

While the advent of artificial intelligence (AI) has obviously changed the world, not every utilization of AI has necessarily ...

Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good. Risk-averse investors should ...